[go: up one dir, main page]

WO2003070160A3 - Antisense modulation of protein expression - Google Patents

Antisense modulation of protein expression Download PDF

Info

Publication number
WO2003070160A3
WO2003070160A3 PCT/US2002/038188 US0238188W WO03070160A3 WO 2003070160 A3 WO2003070160 A3 WO 2003070160A3 US 0238188 W US0238188 W US 0238188W WO 03070160 A3 WO03070160 A3 WO 03070160A3
Authority
WO
WIPO (PCT)
Prior art keywords
map3k8
acetylglucosaminyltransferase
wnt
ras
gated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/038188
Other languages
French (fr)
Other versions
WO2003070160A2 (en
Inventor
Jingfang Ju
Chunli Huang
Haihong Zhong
Jan Fredik Simons
Bruce E Taillon
John S Chant
John A Peyman
Glennda Smithson
Isabelle Millet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/114,153 external-priority patent/US20030185815A1/en
Priority claimed from US10/114,270 external-priority patent/US7033790B2/en
Application filed by CuraGen Corp filed Critical CuraGen Corp
Priority to AU2002364705A priority Critical patent/AU2002364705A1/en
Publication of WO2003070160A2 publication Critical patent/WO2003070160A2/en
Publication of WO2003070160A3 publication Critical patent/WO2003070160A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/0115—N-Acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase (2.4.1.150)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of H-Ras, WNT-7B, acetylglucosaminyltransferase, voltage-gated K chananel, IL-8, ion transport, Map3K8 and Thymidine kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids ancoding H-Ras, WNT-78, acetylglucosaminyltransferase, voltage-gated K channel, IL-8, ion transport, Map3K8 and Thymidine kinase. Methods of using these compounds for modulation of H-Ras, WNT-7B, acetylglucosaminyltransferase, voltage-gated K channel, IL-8, ion transport, Map3K8 and Thymidine kinase expression and for treatment of diseases associated with expression of H-Ras, WNT-7B, acetylglucosaminyltransferase, voltage-gated K channel, IL-8, io n transport, Map3K8 and Thymidine kinase are provided.
PCT/US2002/038188 2001-11-29 2002-11-27 Antisense modulation of protein expression Ceased WO2003070160A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002364705A AU2002364705A1 (en) 2001-11-29 2002-11-27 Antisense modulation of protein expression

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US33414801P 2001-11-29 2001-11-29
US60/334,148 2001-11-29
US33657201P 2001-12-04 2001-12-04
US60/336,572 2001-12-04
US10/114,153 US20030185815A1 (en) 2001-04-03 2002-04-02 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
US10/114,153 2002-04-02
US10/114,270 US7033790B2 (en) 2001-04-03 2002-04-02 Proteins and nucleic acids encoding same
US10/114,270 2002-04-02
US13682602A 2002-05-01 2002-05-01
US10/136,826 2002-05-01

Publications (2)

Publication Number Publication Date
WO2003070160A2 WO2003070160A2 (en) 2003-08-28
WO2003070160A3 true WO2003070160A3 (en) 2004-02-12

Family

ID=31499636

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038188 Ceased WO2003070160A2 (en) 2001-11-29 2002-11-27 Antisense modulation of protein expression

Country Status (2)

Country Link
AU (1) AU2002364705A1 (en)
WO (1) WO2003070160A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003269557A1 (en) * 2002-10-18 2004-05-04 Lg Life Sciences Ltd. Gene families associated with cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074856A2 (en) * 2000-04-03 2001-10-11 Curagen Corporation Wnt-7b-like polypeptides and nucleic acids encoding same
US20020187502A1 (en) * 2001-01-30 2002-12-12 Waterman Marian L. Method of detection and treatment of colon cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074856A2 (en) * 2000-04-03 2001-10-11 Curagen Corporation Wnt-7b-like polypeptides and nucleic acids encoding same
US20020187502A1 (en) * 2001-01-30 2002-12-12 Waterman Marian L. Method of detection and treatment of colon cancer

Also Published As

Publication number Publication date
AU2002364705A8 (en) 2003-09-09
AU2002364705A1 (en) 2003-09-09
WO2003070160A2 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2003012057A3 (en) Antisense modulation of serum amyloid a4 expression
WO2003011887A3 (en) Antisense modulation of apolipoprotein b expression
WO2002092772A3 (en) Antisense modulation of ptp1b expression
WO2003010284A3 (en) Antisense modulation of c-reactive protein expression
WO2004044181A3 (en) Antisense modulation of apolipoprotein b expression
WO2004011610A3 (en) Antisense modulation of polo-like kinase expression
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
WO2003008543A3 (en) Antisense modulation of bcl2-associated x protein expression
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO2003046132A3 (en) Antisense modulation of myd88 expression
WO2003014306A3 (en) Antisense modulation of cholesteryl ester transfer protein expression
WO2003018600A3 (en) Antisense modulation of microsomal triglyceride transfer protein expression
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2002095053A3 (en) Antisense modulation of src-c expression
WO2002062954A3 (en) Antisense modulation of casein kinase 2-beta expression
WO2001031051A3 (en) Antisense modulation of protein kinase c-theta expression
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
WO2003030826A3 (en) Antisense modulation of insulin-like growth factor binding protein 5 expression
WO2002062818A3 (en) Antisense modulation of casein kinase 2-alpha expression
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
WO2003027229A3 (en) Antisense modulation of rip2 expression
WO2003070160A3 (en) Antisense modulation of protein expression
WO2003044167A3 (en) Antisense modulation of human fxr expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP